Journal article

Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years

Helen Marshall, Terry Nolan, Javier Diez Domingo, Lars Rombo, Etienne M Sokal, Josep Mares, Josep M Casanovas, Sherine Kuriyakose, Maarten Leyssen, Jeanne-Marie Jacquet

VACCINE | ELSEVIER SCI LTD | Published : 2010

Abstract

This study compared the long-term persistence of anti-hepatitis A (anti-HAV) and B (anti-HBs) antibodies, 5 years after vaccination of subjects aged 1-11 years with a combined hepatitis A and B vaccine either in a two-dose (0, 6 months, Adult formulation) or a three-dose (0, 1, 6 months, Paediatric formulation) schedule. At the end of the 5 years, all subjects (100%) in both groups continued to have anti-HAV antibodies > or =15mIU/mL, while 94-97% of subjects in both groups had anti-HBs antibody concentrations > or =10mIU/mL. Subjects with anti-HBs antibody concentration < or =10mIU/mL were administered a challenge dose of hepatitis B vaccine. All subjects mounted a vigorous immune response ..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

Drs. HM, TN, JDD and JM declare they received honoraria/paid expert testimony/travel grants from GSK Biologicals; Drs. TN and JMC declare to have received consulting fees in the past 3 years; Drs. LR and EMS declare they have no conflict of interest; Ms. SK, Drs. ML and JMJ are current employees of GSK Biologicals, Drs. ML and JMJ also have stock ownership at GSK Biologicals.GlaxoSmithKline Biologicals was the funding source and was involved in all stages of the study conduct and analysis. GSK Biologicals also funded all costs associated with the development and the publishing of the present manuscript.